CRT develops and commercialises exciting new discoveries in cancer research. We’re the meeting point between academia and industry. Our deep understanding of both perspectives enables us to translate promising research into commercial propositions for the greatest patient benefit and maximum financial return.
Exclusive rights to £300m of cancer research per yearOur marketed drugs include Temodal, Zytiga and Erivedge. What’s next?